Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -103.17 Million USD | 2.79% |
| 2022 | -106.13 Million USD | -30.92% |
| 2021 | -81.07 Million USD | 0.0% |
| 2020 | -81.07 Million USD | 20.59% |
| 2019 | -102.09 Million USD | -29.73% |
| 2018 | -78.69 Million USD | 20.81% |
| 2017 | -99.36 Million USD | -55.46% |
| 2016 | -63.91 Million USD | -184.58% |
| 2015 | -22.46 Million USD | -92455.28% |
| 2014 | 24.32 Thousand USD | 100.03% |
| 2013 | -84.27 Million USD | -186.15% |
| 2012 | -29.45 Million USD | 4.67% |
| 2011 | -30.89 Million USD | -188.12% |
| 2010 | -10.72 Million USD | -94.3% |
| 2009 | -5.51 Million USD | -3323.15% |
| 2008 | 171.22 Thousand USD | 103.93% |
| 2007 | -4.35 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 5.64 Million USD | 112.83% |
| 2024 Q2 | -25.14 Million USD | -545.56% |
| 2023 Q1 | -30.07 Million USD | -12.15% |
| 2023 Q3 | -17.48 Million USD | -64.18% |
| 2023 Q4 | -43.99 Million USD | -151.63% |
| 2023 Q2 | -10.64 Million USD | 64.59% |
| 2023 FY | -103.17 Million USD | 2.79% |
| 2022 Q4 | -26.81 Million USD | 5.8% |
| 2022 Q1 | -31.91 Million USD | 21.42% |
| 2022 Q2 | -18.94 Million USD | 40.63% |
| 2022 Q3 | -28.46 Million USD | -50.25% |
| 2022 FY | -106.13 Million USD | -30.92% |
| 2021 Q4 | -40.6 Million USD | -8.54% |
| 2021 Q1 | -11.86 Million USD | 70.77% |
| 2021 FY | -81.07 Million USD | 0.0% |
| 2021 Q2 | -39.91 Million USD | -236.36% |
| 2021 Q3 | -37.41 Million USD | 6.28% |
| 2020 Q1 | 20.08 Million USD | 153.97% |
| 2020 FY | -81.07 Million USD | 20.59% |
| 2020 Q2 | -32.26 Million USD | -260.66% |
| 2020 Q3 | -30.29 Million USD | 6.09% |
| 2020 Q4 | -40.6 Million USD | -34.03% |
| 2019 Q4 | -37.21 Million USD | -132.58% |
| 2019 Q3 | -15.99 Million USD | 52.17% |
| 2019 FY | -102.09 Million USD | -29.73% |
| 2019 Q2 | -33.44 Million USD | -119.35% |
| 2019 Q1 | -15.24 Million USD | 33.92% |
| 2018 Q4 | -23.07 Million USD | -1.18% |
| 2018 FY | -78.69 Million USD | 20.81% |
| 2018 Q3 | -22.8 Million USD | -214.29% |
| 2018 Q2 | -7.25 Million USD | 71.48% |
| 2018 Q1 | -25.43 Million USD | 6.38% |
| 2017 FY | -99.36 Million USD | -55.46% |
| 2017 Q1 | -19.84 Million USD | -51.32% |
| 2017 Q2 | -27.55 Million USD | -38.86% |
| 2017 Q3 | -26.15 Million USD | 5.07% |
| 2017 Q4 | -27.17 Million USD | -3.89% |
| 2016 Q4 | -13.11 Million USD | 7.17% |
| 2016 FY | -63.91 Million USD | -184.58% |
| 2016 Q2 | -6.95 Million USD | 79.16% |
| 2016 Q1 | -33.39 Million USD | -436.3% |
| 2016 Q3 | -14.12 Million USD | -103.01% |
| 2015 Q1 | 6.65 Million USD | 48.83% |
| 2015 Q4 | 9.92 Million USD | 169.12% |
| 2015 FY | -22.46 Million USD | -92455.28% |
| 2015 Q3 | -14.36 Million USD | 42.22% |
| 2015 Q2 | -24.86 Million USD | -473.54% |
| 2014 FY | 24.32 Thousand USD | 100.03% |
| 2014 Q4 | 4.47 Million USD | -4.09% |
| 2014 Q3 | 4.66 Million USD | 249.81% |
| 2014 Q2 | -3.11 Million USD | 0.64% |
| 2014 Q1 | -3.13 Million USD | 58.88% |
| 2013 Q2 | -9.59 Million USD | -1.46% |
| 2013 FY | -84.27 Million USD | -186.15% |
| 2013 Q1 | -9.45 Million USD | 0.0% |
| 2013 Q3 | -7.48 Million USD | 21.95% |
| 2013 Q4 | -7.61 Million USD | -1.75% |
| 2012 FY | -29.45 Million USD | 4.67% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | -30.89 Million USD | -188.12% |
| 2010 FY | -10.72 Million USD | -94.3% |
| 2009 FY | -5.51 Million USD | -3323.15% |
| 2008 FY | 171.22 Thousand USD | 103.93% |
| 2007 FY | -4.35 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7625.884% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -1377.535% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 294.745% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4842.029% |
| Rebus Holdings, Inc. | -1.02 Million USD | -10015.083% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 258.405% |
| Qrons Inc. | -789.34 Thousand USD | -12970.785% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -16214.47% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -64.817% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -24732.507% |
| Skye Bioscience, Inc. | -37.64 Million USD | -174.072% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -37.633% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1468.919% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -37637.051% |
| SQZ Biotechnologies Company | -79.46 Million USD | -29.837% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -3467.075% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -5567.249% |
| Mesoblast Limited | -87.95 Million USD | -17.302% |
| Marizyme, Inc. | -65.34 Million USD | -57.886% |
| Genus plc | 7.9 Million USD | 1405.998% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -847.267% |
| Pharming Group N.V. | -10.54 Million USD | -878.137% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -4654.963% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2680.791% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -1066.597% |
| ContraFect Corporation | -65.15 Million USD | -58.356% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -2011.595% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -5872.593% |
| IMV Inc. | -36.48 Million USD | -182.779% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1180.123% |
| MultiCell Technologies, Inc. | -380.07 USD | -27145912.84% |
| ONE Bio Corp. | 8.67 Million USD | 1289.103% |
| Accustem Sciences Inc. | -3.74 Million USD | -2653.933% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -99.593% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -8042.3% |
| Q BioMed Inc. | -2.05 Million USD | -4927.738% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2663.832% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -4233.452% |
| Biomind Labs Inc. | -1.21 Million USD | -8396.437% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -72.747% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -3226.292% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1205.487% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -5193.005% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -688827.958% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -550.06% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1673.584% |
| GB Sciences, Inc. | -1.36 Million USD | -7476.97% |
| Alpha Cognition Inc. | -13.77 Million USD | -649.126% |
| HST Global, Inc. | -146.21 Thousand USD | -70465.523% |
| CSL Limited | 2.64 Billion USD | 103.905% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -5779.619% |
| Halberd Corporation | -79.67 Thousand USD | -129391.755% |
| Enzolytics Inc. | -2.17 Million USD | -4639.633% |
| Agentix Corp. | -1.37 Million USD | -7407.861% |
| Resverlogix Corp. | -3.61 Million USD | -2758.001% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -3153.222% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 65.032% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 105379.44% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1589.962% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -2496.88% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -3309.427% |
| AVAX Technologies, Inc. | -6.41 Million USD | -1508.661% |
| Zenith Capital Corp. | -10.59 Million USD | -873.706% |
| Genscript Biotech Corporation | -95.47 Million USD | -8.061% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -443811.243% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -2388.554% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -170602.862% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -5045.533% |
| Kadimastem Ltd | -3.3 Million USD | -3019.487% |
| Helix BioMedix, Inc. | -1.05 Million USD | -9669.724% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -2601.593% |
| BioStem Technologies, Inc. | -8.48 Million USD | -1116.245% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -23275.872% |
| LadRx Corporation | 400.44 Thousand USD | 25864.928% |
| Cell Source, Inc. | -5.32 Million USD | -1838.916% |
| Regen BioPharma, Inc. | 1.02 Million USD | 10180.415% |
| Regen BioPharma, Inc. | 1.02 Million USD | 10180.415% |
| NovAccess Global Inc. | -4.76 Million USD | -2063.343% |
| Affymax, Inc. | -14.42 Million USD | -615.293% |
| Itoco Inc. | -1.86 Million USD | -5420.285% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -2222.409% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -6081.777% |
| Mobile Lads Corp. | -2.26 Million USD | -4458.574% |
| CytoDyn Inc. | -49.84 Million USD | -107.006% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -130445.28% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -45126.497% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -10858.117% |
| SYBLEU INC | -180.3 Thousand USD | -57122.164% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -6297.438% |
| International Stem Cell Corporation | -131 Thousand USD | -78658.665% |
| Bioxytran, Inc. | -4.28 Million USD | -2310.603% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -190005.121% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -3977.62% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -114.624% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -4780.504% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -13112.392% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -3156.75% |
| Neutra Corp. | -233.46 Thousand USD | -44092.428% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -408.471% |
| PureTech Health plc | -65.69 Million USD | -57.045% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -385.146% |
| IXICO plc | -1.17 Million USD | -8658.391% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -939.326% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -80.601% |
| CSL Limited | 2.64 Billion USD | 103.905% |